Evidence map›Paper›PMID 42504027›Full record

ArticleCancer medicine2026

Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.

Lvwen Chen, Lei Cao, Yuxiao Zhao, Hailing Liu, Sanmei Wang, Miao Zhong, Xiran Wang, Jing Zhang, Xiaoyan Qu, Zhengxu Sun and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lvwen ChenDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Lei CaoDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Yuxiao ZhaoDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Hailing LiuDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Sanmei WangDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Miao ZhongDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Xiran WangDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Jing ZhangDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.ORCID https://orcid.org/0000-0002-5302-9873
Xiaoyan QuDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Zhengxu SunDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Lei FanDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Ran LiDepartment of Hematology, Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Funding

China Postdoctoral Science Foundation 2025M772095Clinical Diagnosis and Treatment Technology Innovation Open Bidding and Leader Selecting Project of Jiangsu Province Hospital JBGS202404National Natural Science Foundation of China 82400201National Natural Science Foundation of China 82470186Natural Science Foundation of Jiangsu Province BK20232039Natural Science Foundation of Jiangsu Province BK20241117The Specialized Diseases Clinical Research Fund of Jiangsu Province Hospital XB 202401
6 · The paper itself

Abstract

The incidence of primary central nervous system low-grade B-cell lymphoma (PCNSL-LG) is rare. We aimed to provide the first large-scale analysis of treatment modalities, survival trends, and prognostic factors for PCNSL-LG. Patient data diagnosed between 2000 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. A total of 267 adult PCNSL-LG patients were included. The year of diagnosis was divided into the time period-1 (2000-2009) and the time period-2 (2010-2021). Radiotherapy alone usage remained stable over time (27.34% vs. 30.22%, p = 0.605). Chemotherapy alone showed a modest, non-significant increase (25.00% vs. 31.66%, p = 0.229), while combined chemoradiotherapy declined significantly from 29.69% to 15.11% (p = 0.004). The 1-, 5-, and 10-year overall survival (OS) rates for all PCNSL-LG patients were 84.3%, 73.4%, and 61.8%, respectively. Overall survival improved significantly, with median OS extending from 11.25 years in period-1 to not reached in period-2 (HR 0.46, 95% CI: 0.28-0.74; p = 0.001). Surgery was associated with improved outcomes compared with non-surgical management (HR 0.47, 95% CI: 0.31-0.72, p < 0.001). In patients with MALT lymphoma histology, no significant prognostic difference was observed across treatment modalities (p = 0.838). This study underscores a marked improvement in survival among PCNSL-LG patients over the past two decades and offers valuable insights for optimizing clinical management and improving patient outcomes.

Indexed as

Central Nervous System NeoplasmsLymphoma, B-CellAdultAgedFemaleHumansMaleMiddle AgedNeoplasm GradingPrognosisSEER ProgramSurvival Ratelow‐grade B‐cell lymphomaPCNSLprognostic factorsSEERsurvival outcomes

Identifiers

PMID42504027
PMCPMC13402853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.